Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CEA-Alexa 488 is a fluorescently labeled monoclonal antibody conjugate designed for fluorescence-guided surgery (FGS). It consists of a monoclonal antibody specific for carcinoembryonic antigen (CEA) covalently linked to the Alexa Fluor 488 fluorophore. CEA is a cell-surface glycoprotein that is overexpressed in several solid tumors, including pancreatic and colorectal cancers. By binding to CEA-expressing cells, the conjugate allows for the real-time identification and localization of primary tumors and sub-millimeter metastatic lesions using fluorescence laparoscopy. This technology is intended to assist surgeons in achieving complete tumor resection and identifying margins that are not visible under standard bright-light conditions. The agent has been primarily investigated in preclinical orthotopic mouse models of human pancreatic cancer by OncoFluor and researchers at the University of California San Diego.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-CEA-Alexa 488.